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Abstract
Prostatic neoplasms are not uniformly distributed with-
in the prostate volume. With recent developments
in three-dimensional intensity-modulated and image-
guided radiation therapy, it is possible to treat differ-
ent volumes within the prostate to different thresholds
of doses. This approach has the potential to adapt the
dose to the biologic aggressiveness of various clusters
of tumor cells within the gland. The definition of tumor
burden volume in prostate cancer can be facilitated by
the use of magnetic resonance spectroscopy (MRS).
The increasing sensitivity and specificity of MRS to the
prostate is causing new interest in its potential role in
the definition of target subvolumes at higher risk of
failure following radical radiotherapy. Prostate MRS
might also play a role as a noninvasive predictive factor
for tumor response and treatment outcome. We review
the use of MRS in radiation therapy for prostate can-
cer by evaluating its accuracy in the classification of
aggressive cancer regions and target definition; its
current role in the radiotherapy planning process, with
special interest in technical issues behind the success-
ful inclusion of MRS in clinical use; and available early
experiences as a prognostic tool.
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Introduction
Further to the development of three-dimensional (3D) con-
formal, intensity-modulated, image-guided, adaptive radia-
tion therapy, major changes have occurred in the last three
decades in the treatment planning of nonmetastatic pros-
tate cancer. These techniques have significantly improved
treatment precision, allowing for greater sparing of critical
organ and delivery of escalated doses of radiation to the
target volume.
It is now feasible to treat different volumes within the
prostate with different thresholds of doses, with the potential
to adapt the dose delivered to each subtarget area to the
biologic aggressiveness of the various clusters of tumor popu-
lation present in the gland.
A variety of magnetic resonance imaging (MRI) techniques
is used nowadays in the field of cancer research, including
dynamic contrast-enhanced (DCE) MRI, functional MRI, and
diffusion-weighted MRI [1–6]. In the clinical practice of radia-
tion therapy, MRI is routinely added to conventional computed
tomography (CT) planning to improve target volume definition.
Unfortunately, although standard MRI scans are able to pro-
vide extremely detailed anatomic imaging, their findings do not
always correlate with tumor biology. Magnetic resonance spec-
troscopy (MRS) and magnetic resonance spectroscopy im-
aging (MRSI) have been successfully used in other regions
(i.e., brain, head, and neck) to measure biochemical changes
within the target volume, detect metabolic markers of different
tumor phenotypes [7], and characterize tumor microenviron-
ments in terms of blood volume and vessel permeability. The
sensitivity and specificity of MRS-MRSI techniques for prostate
studies increased significantly in the last few years, causing
new interest for their potential role as a tool for the definition
of target subvolumes at higher risk of failure following radical
radiotherapy. Similarly to other tumor sites, prostate MRS-
MRSI might also play a role as a noninvasive predictive factor
of tumor response and treatment outcome.
The aim of this paper is to provide a comprehensive review
of the use of MRS-MRSI in radiation therapy for prostate
cancer by evaluating: their accuracy in terms of target definition
and classification of aggressive cancer regions; their current
role in the radiotherapy treatment planning process, with spe-
cial interest in technical issues behind the successful clinical
use of MRS data; and available early experiences as a diag-
nostic tool for follow-up after radiotherapy.
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Search Criteria
To provide a comprehensive review of the use of MRS-MRSI
in radiation oncology for prostate cancer, we conducted an
electronic search for relevant studies in databases such as
PubMed, Medline, and EMBASE. During this search, a list of
keywords relevant to the subject of review was used. Results
were limited to articles published in English peer-reviewed
journals between 1980 and 2007. Further studies were lo-
cated by a search in literature references identified by the
first search of the review.
MRS
MRS employs nuclear magnetic resonance techniques to
investigate the metabolism of chemicals in the living body.
Different chemicals containing the same nucleus exhibit
characteristic chemical shifts in resonance frequency, al-
lowing the chemical form of the element to be identified.
Thus, MRS provides a noninvasive window on the metabo-
lism of the organ under investigation.
A significant number of metabolites found in normal and
pathological prostates contain either 1H or 31P. 31P spectros-
copy provides information on metabolites involved in providing
energy for cellular processes. Researchers demonstrated that
malignant prostate cancers are characterized by significantly
decreased levels of phosphocreatine and increased levels of
phosphomonoesters, compared to healthy prostates [8–11].
However, there have been no published recent studies
on 31P likely due to a shift in researchers’ interest toward
proton MRS (1H MRS) since the development of efficient
water and fat-suppression techniques.
As a result, the majority of investigations on prostate can-
cer with MRS employed 1H MRS. Molecules that can be
studied with 1H MRS include choline, citrate, lactate, and
creatine, as well as water and lipids, which are usually sup-
pressed. In the prostate, an elevated level of choline may be
an indicator of active tumor, as choline is essential for cellu-
lar membrane composition and repair. Areas that are signifi-
cantly infiltrated by prostate adenocarcinoma have a higher
choline/citrate ratio compared with normal prostatic tissues
and benign hypertrophy [12,13]. Creatine helps in supplying
energy to muscle cells; because of its close proximity to the
choline peak, it is often added to the choline peak when the
choline/citrate ratio is calculated.
All the articles further reviewed in this manuscript refer to
1H MRS. In addition, MRS and spectroscopic imaging are
referred to in the literature by a number of names and ab-
breviations, including MRS, MRSI, and chemical shift im-
aging (CSI). In this article, for consistency, we chose to refer
to all spectroscopic variants as MRS.
MRS in Radiotherapy Treatment Planning
A peculiar characteristic of prostate adenocarcinoma is its
multifocality and the synchronous presence of different clus-
ters of aggressiveness within the tumor volume.
Several analyses of clinical trials suggest that an in-
creased radiation dose to the prostate is associated with a
reduced rate of biochemical failure and may, therefore, in-
crease local control rates and decrease the risk for distant
metastasis and overall mortality rate [14–18]. This observa-
tion is important for the management of intermediate-risk
and high-risk prostate cancer patients; however, an in-
creased radiation dose may be associated with an increased
risk of treatment morbidity [19].
Traditionally, the whole prostate gland had been treated
with a homogenous high-dose level, with dose escalation car-
ried out for the whole gland. It is possible, however, to adopt
an approach whereby the whole prostate is treated with a
homogenous dose while the tumor burden area, as detected
by 3D-MRS, is treated to a higher dose. The higher dose
should be derived according to tumor control probability (TCP)
and aimed at maintaining the dose to surrounding organs.
So far, this has been realized using either prostate brachy-
therapy or intensity-modulated radiation therapy (IMRT) to
produce inhomogeneous gradients of dose within the gland
and to administer a boost to one or more so-called dominant
intraprostatic lesions (DILs).
Coregistration of MRI/MRS with CT/Ultrasound
To be used in radiation therapy planning, MRS images
must be accurately matched and coregistered with images
providing the anatomic information of the patient, such as CT
and MR. Such coregistration should be capable of taking into
account deformations, especially if organs are deformable as
it is in the case of the prostate. Variations to be taken into
account include interfraction and intrafraction movements,
as well as prostate displacement and deformation, which are
especially relevant if an endorectal (ER) coil is used for MRS
examination. The standard deviation of prostate movement
over the course of radiation therapy, as reviewed by Langen
and Jones [20], reported ranges in the anterior–posterior
direction from 1.5 to 4.5 mm, in the superior– inferior direc-
tion from 1.7 to 3.9 mm, and in the left–right direction from
0.7 to 1.9 mm. The maximum prostate movement over one
fraction in one of the studies was found to be 13.86, 9.88, and
1.40 mm in the anterior–posterior, superior– inferior, and
left–right directions, respectively [21].
The presence of an ER coil, although required for op-
timal MRS of the prostate with high resolution [22], adds
additional displacement, which is a potential problem for the
radiotherapy treatment planning of the prostate. In addition,
T2-weighted images of the prostate obtained with the ER coil
provide much higher soft-tissue contrast of the prostate than
normally provided by routine pelvic scans that do not em-
ploy an ER coil [23]. However, the coil deforms the prostate
during MR/MRS investigation, changing its geometry from
the treatment geometry. There have been a number of
studies investigating the issue of the coregistration of MRS
images distorted by an ER coil with MR/CT, and there are
several approaches to overcoming this problem at present.
One of the methods proposed was based on the assump-
tion that the relative position of points within the prostate is
maintained with respect to the axial contours of the prostate
[24,25]. A second method involved the visual transfer of the
location of dominant lesions [26,27], whereas other methods
took into account either control points selected from the
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contour of the prostate as an input to a transformation
algorithm [28,29] or all points contained in the narrow band
around the delineated prostate [29]. The idea of registration
by mutual information, involving the correlation of intensity
levels (gray scale) between pixels in two images, was also
implemented [30]. Other registration techniques include bio-
mechanical modeling of soft tissues [31] and the use of intra-
prostatic fiducial gold markers as reference points [32].
With one exception [31], differences in density and elas-
ticity parameters within prostatic tissues were not taken into
account in the abovementioned studies dealing with prob-
lems imposed by ER coil–related prostate deformation. The
authors argued that the voxel size of MRS is generally very
coarse (currently f5 mm) compared to anatomic images
and, therefore, increased registration accuracy by more
advanced methods may not be necessary for prostate map-
ping purpose. However, one can expect advances in MRS
leading to decreased voxel size and more precise tumor
burden localization.
One way of overcoming the problem of the registration of
coil-deformed and nondeformed prostate volumes is by per-
forming MRS without the ER coil. A two-dimensional MRS
study using external surface coils for the evaluation of prostate
cancer provided comparable detection accuracy to ER sur-
face coil CSI [33]. In addition, 3D-MRS of the prostate was
found to be feasible using a spine array surface coil at 1.5 T.
However, spectral quality and signal-to-noise ratio are clearly
inferior to 3D-MRSI examinations with ER coils [34]. Our ex-
perience at Townsville Cancer Center (Queensland, Australia)
confirms that a combination of multiple external coil MRS is
feasible with diagnostic signal-to-noise ratio.
Other solutions can be the use of an ER balloon during
radiation therapy, the shape of which is comparable to the
MRS coil. The registration of prostatic volume at different
rectal-filling levels is also a way of assessing the internal
margin, accounting for expected physiological movement
and variations in the geometry of clinical target volume
(CTV) or gross tumor volume during the administration of
radiation therapy.
Target Definition with MRS
An ideal imaging technique for target volume localization
should be highly sensitive to and specific for cancer de-
tection, be able to provide enough information for precise
tumor delineation (including extensions outside the organ’s
anatomic boundaries), and allow the prediction of tumor
response to radiation.
In a number of studies investigating the sensitivity and
specificity of MRS for locating prostate adenocarcinoma,
MRS sensitivity was found to be within the range 38.5% to
77%, and specificity was found to be between 38.5% and
78% [22,35,36]. Combined MRI/MRS had increased sensi-
tivity, up to 100% [37]. Differences between studies can be
explained by varying methodologies, difficulties in ensuring
the correspondence of transrectal ultrasound biopsy spatial
accuracies to suspicious areas onMRI and MRS, differences
in MRS coverage of the target, and limitations of the scan-
ning and postprocessing software used.
The sensitivity of MRS appears to improve with higher
Gleason score, with detection rate being greatest for tumors
with a Gleason score of z 4 + 3 = 7 [38].
The value of MRS for the localization of cancer nodules
within the prostate volume is supported by studies of MRS use
to direct prostate biopsy. For patients with previous negative
biopsies but other signs of prostate cancer, such as elevated
prostate-specific antigen (PSA) and positive digital rectal
examination, it has been shown that the use of MRI/MRS
combination may reduce the rate of false-negative biopsies
and hence decrease the need for more extensive biopsy
protocols and/or repeated biopsy procedures [39]. For sex-
tant localization of prostate cancer, MRI and MRS are found
to be more sensitive but less specific than biopsy, with sen-
sitivities of 67% for MRI, 76% for MRS, and 50% for biopsy,
and with specificities of 69% for MRI, 68% for MRS, and 82%
for biopsy [40]. In one study, the authors found that two of
seven patients would have had cancers missed if transrectal
ultrasound biopsy had not been directed at abnormal areas
detected by combined MRI and MRSI [22].
Coakley et al. [41] compared MRI, 3D-MRS, and a combi-
nation of both with respect to their ability to assess tumor
volume. Not all three measurements could be performed
for each tumor nodule because some nodules were not de-
tected with all three methods. For all techniques, systematic
overestimation of tumor volume occurred, and all techniques
were more accurate for higher tumor volumes. Tumor vol-
ume measurements with all methods were positively cor-
related with histopathological tumor volume for nodules >
0.5 cm3, but only measurements with MRS and a combina-
tion of MRI and MRS demonstrated statistical significance.
It could be concluded that the addition of MRS to MRI in-
creases the overall accuracy of prostate cancer tumor vol-
ume measurement, although measurement variability limits
consistent quantitative tumor volume estimation, particularly
for small tumors. In a study by Hom et al. [42], overestimation
of tumor volume was observed once again when a true-
positive lesion is defined with MRI and MRS by size alone.
Given the reported limitation of MRI and MRS to assess
tumor volume, the authors concluded that the assumption
that a technically successful dose escalation in spectroscopi-
cally suspicious locations implies improved clinical outcome
must be viewed with caution [43].
Results support the use of 3D-MRS as a predictor of ex-
tracapsular extension (ECE). A combination of volumetric
data from MRS and anatomic display of MRI significantly
improves the evaluation of ECE. Patients with the least ex-
tensive tumor demonstrated byMRSwere found to have only
a 6% risk of ECE, whereas patients with the most extensive
tumor (more than four cancer voxels per section) had an 80%
risk of ECE [44].
In terms of tumor burden delineation, the classification
of MRS voxels as described by Kurhanewicz et al. [12] is
often used. A voxel is classified as normal, suspicious for
cancer, or very suspicious for cancer. Furthermore, a voxel
may contain nondiagnostic levels of metabolites or an arti-
fact that obscures the metabolite frequency range. Voxels
are considered suspicious for cancer if (choline + creatine)/
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citrate is at least 2 SD above the average ratio for the nor-
mal peripheral zone. Voxels are considered very suspicious
for cancer if (choline + creatine)/citrate is > 3 SD above the
average ratio.
The aggressiveness of prostate cancer, which in most
cases correlates with the Gleason score from biopsy, is a
key predictor of treatment outcome [45–47]. The (choline +
creatine)/citrate ratio in the lesion from MRS examination
was found to correlate with the Gleason grade, with eleva-
tion of choline and reduction of citrate indicating increased
cancer aggressiveness [38]. Although there was an over-
lap between the metabolites ratio at various Gleason score
levels [38], this finding provides an important rationale for
adding MRI/MRS to the pretreatment evaluation of prostate
cancer patients.
MRS-Guided Brachytherapy
Brachytherapy is one of the techniques capable of de-
livering intentionally inhomogeneous dose distribution to the
target. There exist a number of studies investigating the fea-
sibility of including MRS data in brachytherapy planning.
Zaider et al. [24] employed a biologically based treatment
planning optimization module for brachytherapy to calculate
TCP according to an expression developed previously [48]
and to study dose escalation in MRS-defined tumor lesions
within the prostate. MRS was registered to ultrasound im-
ages, and this information was incorporated into the treat-
ment planning system. The prescription dose was 144 Gy
using 125I seeds; the dose to intraprostatic lesion was set to
be at a minimum of 120% of the prescription dose with no
upper limit. They have shown that it is theoretically possible
to achieve tumor dose escalation in MRS-identified intra-
prostatic tumor deposits without concomitant delivery of
escalated doses to the urethra (dose bounds of 100–120%
of the prescription dose). As can be expected, the magnitude
of TCP increase appeared to be greater when the tumor was
well localized.
DiBiase et al. [26] created standard 3D brachytherapy
plans that prescribed 145 Gy, using 125I, to the planning tar-
get volume, so that 100% of the prostate received the
prescribed dose. MRS-defined boost volumes were then
manually planned, using 125I as well. In 14 of 15 patients
planned with MRS, data were successfully incorporated into
their treatment plan and used to increase the radiation dose
prescription to 130% in MRS-defined volumes. In one patient,
MRS revealed significant multifocal disease (four separate
cancer foci) that made focal boosts impractical. Postimplant
dosimetry confirmed a median V100 of 95% (range, 89–
98%) in the 15 evaluated patients for the prescription dose
of 145 Gy to the target volume. The median BTV100 for the
abnormal citrate region was 90% (range, 80–100%). Urethral
and rectal dose–volume histogramswere within normal limits.
Morbidity was comparable with that for conventionally treated
patients. Although this series was small and had short follow-
up, MRS-guided implants are feasible and warrant further
investigation as a means to improve the therapeutic ratio in
prostate treatment.
Pouliot et al. [27] conducted another brachytherapy plan-
ning study to escalate dose to MRS-defined lesions. Treat-
ment planning was performed for 10 patients, of which
8 had two DILs in the prostate and 2 had a single lesion.
The dose to the DIL could be escalated to a minimum of
120% while the entire prostate is treated simultaneously,
without increasing the dose to surrounding normal tissues.
Higher boost levels between 150% and 170% were deemed
feasible, but at the cost of slightly larger doses delivered to
the rectum and urethra.
MRS-Guided IMRT
Another technique that is capable of delivering an inho-
mogeneous dose distribution is IMRT. IMRT was initially
proposed for the irradiation of tumors with close proximity
to sensitive organs, allowing an increase in dose to target
while sparing organs at risk [49]. However, combined with
inverse planning algorithms, it can simultaneously deliver
different prescribed dose levels to intraprostatic lesions and
to the remainder of the prostate volume.
Pickett et al. [50] demonstrated that the combined use of
static field IMRTand MRI/MRS allowed a treatment plan de-
sign that would deliver higher doses to tumor-bearing regions
of the gland without exceeding the tolerance of surrounding
normal tissues. In this study, treatment plans involved one
region of the prostate (DIL) being treated with a dose of
90 Gy while the whole prostate is treated with > 70 Gy.
MRI/MRS was performed with the rectum dilated, and CTV
was generated by adding prostate volumes contoured on
CT and MR studies as an attempt to consider all likely posi-
tions of the prostate during treatment. The spectroscopic
threshold for DIL was placed at 3 SD above the levels
expected for normal prostatic peripheral zone tissues. The
transfer of the dominant lesion from the MRI/MRS study to
CT was performed by aligning bony pelvic and femoral
anatomy. The authors achieved acceptable dose distribu-
tions when the dominant lesion was encompassed by a
90-Gy isodose without margins. Prostate movement was
tracked during treatment delivery using gold seeds viewed
with online portal imaging. Static field IMRT provided 25%
more dose to the dominant lesion than traditional 3D confor-
mal radiotherapy techniques. Based on dose–volume histo-
grams, the authors concluded that there appeared to be an
increase in the projected probability of tumor control and a
decrease in the projected complication probability.
The same group evaluated the feasibility of dose escala-
tion to parts of the prostate using three methods: forward and
inversely planned segmental multileaf collimator (SMLC),
intensity-modulated radiotherapy, and sequential tomother-
apy (ST) [51]. CTV was defined as prostate volume on CT.
Planning target volume (PTV) was obtained by expanding
the CTV by 5 mm in all directions without overlapping other
defined organs. Regions of prostate for dose escalation were
two MRS-identified DILs: one at the left base and the other at
the right apex of the prostate. The transfer of lesions from
MRI/MRS to CT images was performed by visual approxima-
tion. They were planned to be treated with 90 Gy while the
prostate gland was treated to a dose of 75.6 Gy. Planning
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dose–volume thresholds for the rectal wall and bladder were
estimated to cause a Radiation Therapy Oncology Group
(RTOG) grade 2 complication rate of < 10%. Once again,
prostate movement was monitored with gold seeds implanted
in the prostate and was tracked with an electronic portal image
device. It was concluded that the dose escalation to MRS-
defined DILs within chosen dose constrains was feasible with
all three methods; however, whether the treatment scheme
will prolong patient survival remains to be determined. ST pro-
vided the best dose conformity and the highest dose (100 Gy
compared with 97.8 Gy for the inverse SMLC plan and
93.2 Gy for the forward SMLC plan). Dose inhomogeneity
inside the PTV was similar for all plans, whereas forward
SMLC provided a more homogenous dose distribution in DILs.
Inverse planning techniques were better at protecting the rec-
tal wall, with inverse SMLC proving to be slightly better [51].
Another study of a boost dose to a selected region of
prostate was conducted by van Lin et al. [52]. Radiotherapy
treatment plans for five patients were prepared in this study.
For each patient, a single DIL volume was defined by
combined DCE-MRI and MRS. For each patient, four gold
markers were implanted in the prostate and used during the
coregistration of CT and MR image sets. CTV was defined
as the prostate volume on MR images and transferred to CT
images. DIL volume was transferred to CT images using the
fusion window tools of a commercial treatment planning
system. The dose prescribed to the PTV (prostate volume
plus 7 mm of isotropic margin) was 70 Gy, whereas the DIL
volume plus a 5-mm isotropic margin was treated up to a
total dose of 90 Gy. For each patient, a second IMRT plan
was also realized with a prescribed dose of 78 Gy to the
prostate volume plus 7 mm of margin, without the boost
dose. Plans were compared in terms of TCP for prostate and
DIL, as well as normal tissue complication probability for the
rectal wall with serious rectal toxicity as end point. The re-
sults have indicated that DIL IMRT may improve the thera-
peutic ratio by decreasing the normal tissue complication
probability with an unchanged high TCP. The complication
probability of the rectal wall was decreased by 1% to 3% to a
mean of 4% in four of five patients [52].
These studies show that radiotherapy planning using
MRS-defined regions for boost dose is technically feasible
with IMRT. The choice of method for volume transfer be-
tween MR and CT images is still an open issue, whether the
transfer is conducted by visual approximation, by the use
of rectal balloon during both CT and MR examinations, or
by other means. In addition, the boost dose to which DILs
should be irradiated has not been adequately investigated.
However, it can be expected that adding a margin to the
dominant lesion to define the volume for boost dose should
improve lesion coverage.
It needs to be stressed that IMRT delivery differs signif-
icantly from brachytherapy techniques. In high-dose brachy-
therapy, the target volume is immobilized with needles; in
low-dose brachytherapy, radioactive seeds are implanted
into the prostate volume and move together with it. There-
fore, organ motion does not influence treatment outcome
and does not need to be considered in treatment planning or
brachytherapy quality assurance processes. Oppositely, in
IMRT techniques, internal organ motion and the manner by
which it is accounted for are important factors influencing
the precision of dose delivery. It is paramount for success-
ful IMRT delivery that the daily spatial location of the target
volume is known—or, at the very least, that its distribution
can be predicted. To improve the precision of IMRT delivery,
the process of adaptive radiotherapy was introduced and is
being further developed [53–55]. It uses target image feed-
back and either treatment plan or patient position adjust-
ments to account for day-to-day variations in target position.
Adaptive radiotherapy has the potential to allow a precise
and safe delivery of MRS-guided IMRT plans with dose
escalation to intraprostatic dominant lesion.
MRS in Follow-Up Treatment
The most common method used to confirm the resolution
of prostate cancer after definitive radiotherapy is the serum
PSA test. However, bouncing PSA values are common after
external beam radiation therapy [56]. It can take up to 4 years
for PSA results to reach a nadir after external radiotherapy
[57]. Even when a nadir is achieved, it is often difficult to
interpret [58,59], especially in patients undergoing androgen
deprivation therapy because of the direct effect on PSA
production. In addition, the use of MRI in detecting recur-
rence after therapy is not well established, partly because the
exact site of local, regional, or distant recurrence in patients
with rising PSA is, in most cases, uncertain, which in turn
makes the targeting of an imaging site difficult [43].
The ability of MRI to depict residual/recurrent disease
after radiotherapy is limited because of posttreatment
changes, including prostatic shrinkage, development of dif-
fuse low T2-weighted signal intensity in the gland, and in-
distinctness of normal zonal anatomy [60]. In addition, even
if the tumor is detected, MRI does not have the ability to
distinguish active tumor from treated tumor. MRS, which de-
tects abnormal metabolism rather than abnormal anatomy,
has shown considerable promise in the local evaluation of
prostate cancer after treatment.
MRS can diagnose metabolic atrophy, which is indica-
tive of successful treatment because the growth of normal
or abnormal cells cannot occur without metabolism. Thus,
MRS has the potential to be an earlier indicator for the
resolution of local disease compared to the PSA nadir. If
supported by longer follow-up, the time to metabolic atrophy
may be used as an adjunct to PSA determination for assess-
ing local control after both permanent prostate seed im-
plantation and external beam radiotherapy [61,62]. Benign
PSA blips were not associated with an increase in metabolic
activity, suggesting that these blips are secondary to the
death of epithelial cells leaking into the bloodstream [62].
This study also suggests that, when used in conjunction with
PSA determination and biopsy, MRS may provide a greater
level of confidence when assessing local control.
Pitfalls of MRS
In a study by Kaji et al. [13], the addition of MRS to MRI
resulted in a significant increase in the accuracy (52–75%)
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and specificity (26–66%) of tumor detection. However, post-
biopsy hemorrhage may hamper tumor detection in the pros-
tate, leading to either underestimation or overestimation of
tumor presence and local extent. Regions of extensive hem-
orrhage can result in either loss of all prostatic metabolites
or overcalling of cancer due to a larger decrease in citrate
rather than choline. MRS can accurately identify tissues
underlying hemorrhage approximately 62% of the time. In
addition, MRS spectral degradation was found to be in-
versely related to time from biopsy, with mean percentages
of degraded peripheral zone voxels of 18.5% within 8 weeks
after biopsy and 7% after 8 weeks [63]. Therefore, MRS
should be delayed for at least 4 to 8 weeks after prostate
biopsy [63–65].
Hormone therapy, one of the treatment options for pros-
tate cancer, also influences the results of MRS by changing
the metabolism of the prostate. In a study by Mueller-Lisse
et al. [66], it has been shown that there was a significant
time-dependent loss of prostatic metabolites during hormone
deprivation therapy, leading to complete loss of metabolites
after a longer time of therapy. In a group of patients under-
going short-term androgen deprivation therapy (1–6 weeks),
the metabolic pattern of both the normal prostate and pros-
tate cancer was similar to that of untreated patients. In 25%of
patients receiving long-term hormonal therapy (> 34 weeks),
there was complete loss of metabolites on MRS; in 69% of
these patients, loss of detectable citrate was observed. In
the absence of citrate in the spectra, residual prostate can-
cer could be detected by elevated choline levels (choline/
creatine ratio > 1.5). In some of the cases, when creatine was
also reduced to noise level, the presence of cancer could
be still detected by the choline peak in the proton spectrum,
with a signal-to-noise ratio of > 5. This observation was also
confirmed by imaging and biopsy diagnosis of cancer. At
each point of hormonal therapy, a significant difference be-
tween the metabolic spectra of healthy prostate tissue and
the metabolic spectra of malignant prostate tissue was seen
[66]. However, it was concluded that within 4 months of an-
drogen deprivation therapy, combined MRI and 3D-MRS had
the same accuracy in localizing prostate cancer as in non-
treated patients [67].
The production, storage, and secretion of prostatic cit-
rate are hormone-dependent [68]. Results suggesting an
association between serum PSA levels and citrate detec-
tion in the prostate after androgen deprivation therapy have
also been reported [69]. After hormonal therapy, patients
with detectable citrate on MRS had PSA levels significantly
higher than those of patients without detectable citrate on
MRS [69].
For these reasons, the use of citrate as a reference for
detecting the increase in choline levels is questionable. A
patient with elevated choline level and high citrate level may
have the same metabolite ratio as a patient with much lower
choline level and low citrate level.
As well as the influence of postbiopsy changes and hor-
monal therapy, there are a number of pitfalls associated with
MRS. MRS is technically demanding and needs specialized
software and a high level of expertise, both in performing
MRS and in evaluating results. The quality of spectra (signal-
to-noise ratio) varies from site to site, depending on equip-
ment and signal acquisition techniques. There is an interplay
between MRS resolution and signal-to-noise ratio; for ac-
ceptable signal-to-noise ratio, MRS resolution often has to
be crude. Consequently, poor spatial resolution causes dif-
ficulties in the interpretation of signal from voxels that overlap
different tissue regions (e.g., voxels on the edge of prostate
and muscle or fat). Additionally, there are no established
protocols for MRS signal processing; hence, the process is
operator-dependent. For each 3D prostate MRS, > 4000
single spectra can be produced, making manual evaluation
an extremely time-consuming and complex task.
Finally, DICOM 3 and DICOM RT conformance state-
ments (digital imaging communication protocols for diagnos-
tic imaging and radiotherapy) are not fully implemented for
MRS. As a consequence, image and data transfers between
postprocessing workstations suffer from lack of mutual stan-
dards between manufacturers.
Summary and Future Challenges
Biologic imaging, including MRS, has the potential for chang-
ing radiation therapy by precise tumor localization. The re-
gion of high (choline + creatine)/citrate ratio on prostate
MRS is most commonly considered as the biologic target
volume for which an additional dose can be delivered. As
such, the ratio of metabolites becomes a functional determi-
nant of cancer location within the prostate. Future studies
should further clarify the role of each detectable metabolite.
Ideally, with improved MRS acquisition, creatine should not
be added to choline as there is no indication of its relation
with tumor aggressiveness.
The use of MRS to distinguish between normal and can-
cerous areas has great potential in enhancing the therapeu-
tic ratio of brachytherapy and IMRT. Studies conducted to
date show that delivering a boost dose to DILs within the
prostate gland is feasible using both techniques, with a cor-
responding decrease in normal tissue complication proba-
bility. Further work is required to analyze the exact level of
dose escalation needed. Ideally, biologic imaging methods
could be used to determine the level and location of boost
dose on a patient-specific basis.
There is considerable evidence from the work presented
in this review that supports the value of MRS in prostate
cancer treatment. To date, however, trials have been small
and somewhat restricted in scope, and there is a need to
undertake larger clinical trials covering a greater range of
grade, number, and location of intraprostatic lesion to better
define the full usefulness of MRS in prostate treatment. This
work should also provide a better understanding of when
and how to best incorporate MRS such that it leads to im-
proved treatment outcome.
Biologic and technical pitfalls of MRS need to be ad-
dressed before its introduction into routine clinical practice.
Interoperator differences in MRS evaluation should be
decreased either by the introduction of new protocols for
spectral processing or by the automation of this process.
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Indeed, developments in spectral processing methodology
and the use of innovative signal processing methods such as
signal entropy analysis [70] can aid in both consistency of
results and improvement in metabolite detection sensitivity
and specificity.
Improved analysis may also be gained from coanalysis
with tissue segmentation information and statistical methods
that include comparisons with normal metabolite concen-
trations, which vary as a function of location and subject
parameters, thus gaining more information without neces-
sarily increasing the signal-to-noise ratio.
An automated pattern recognition of the spectra is a
promising approach to overcoming the difficulties associated
with manual evaluation [71]. An expert system trained on a
set of reference data showed potential for being less sensi-
tive to high noise levels, automatically identifying unusable
spectra and decreasing overall spectra evaluation time.
Additionally, progress in signal acquisition technology and
hardware can lead to improved signal-to-noise ratio, allowing
for smaller voxel dimensions with a corresponding increase
in spatial resolution and more precise metabolite maps of
cancer activity within the target volume. The installation
base of 3-T MRI scanners is constantly growing. A higher
static field strength is desirable especially for spectroscopy in
terms of providing improved signal-to-noise ratios, higher
resolution, and shorter scan times, and of improving the
utilization of external coils instead of ER coils [72]. It is not
clear which of these potential advantages will be the most
important in upcoming clinical 3T protocols. Adaptive radio-
therapy for prostate cancer IMRT, although not widely avail-
able yet, will eventually be used in studies evaluating the
clinical benefit of MRS-supported IMRT treatments.
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